Joseph Levy MedicReS World Congress 2013 - 1
-
Upload
medicres -
Category
Health & Medicine
-
view
397 -
download
5
Transcript of Joseph Levy MedicReS World Congress 2013 - 1
![Page 1: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/1.jpg)
1
Adaptive Design in Clinical Trials
Joseph Levy, PhDTeva Pharmaceutical Industries
MedicReS 2013 Istanbul
![Page 2: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/2.jpg)
2
Outline
What are adaptive designs? Review of possible adaptations Take home message
![Page 3: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/3.jpg)
3
The adaptive design principle
![Page 4: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/4.jpg)
4
Three definitions of adaptive designs
By adaptive design we refer to a clinical study design that uses accumulating data to decide how to modify aspects of the study as it continues, without undermining the validity and integrity of the trial.
PhRMA White Paper (2006)
A study design is called “adaptive” if statistical methodology allows the modification of a design element (e.g. sample-size, randomization ratio, number of treatment arms) at an interim analysis with full control of the type I error.
EMEA Reflection Paper (2007)
An adaptive design clinical study is defined as a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study.
FDA Draft Guidance for Industry (2010)
4
![Page 5: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/5.jpg)
5
Adaptation
An adaptation is defined as a change or modification made to a clinical trial before and during the conduct of the study.
Examples include Relax inclusion/exclusion criteria Change study endpoints Modify dose and treatment duration
etc.
![Page 6: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/6.jpg)
6
Prospective adaptations Adaptive randomization Interim analysis Stopping trial early due to safety, futility, or efficacy Sample size re-estimation
etc.
Concurrent adaptations Trial procedures - implemented by protocol amendments
Retrospective adaptations Statistical procedures - implemented by statistical analysis plan
prior to database lock and/or data unblinding
Types of adaptations
![Page 7: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/7.jpg)
7
Adaptive trial designs
Adaptive randomization Group sequential design Sample size re-estimation Drop-the-loser (or Pick-the-winner) Adaptive dose finding Biomarker-adaptive design Adaptive treatment-switching Adaptive-hypotheses design Seamless Phase I/II or Phase II/III Multiple adaptations
![Page 8: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/8.jpg)
8
Adaptive randomization
A design that allows modification of randomization schedules Unequal probabilities of treatment assignment Increase the probability of success
Types of adaptive randomization Treatment-adaptive Covariate-adaptive Response-adaptive
Comments Randomization schedule may not be available prior to the conduct of
the study. It may not be feasible for a large trial or a trial with a relatively long
treatment duration.
![Page 9: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/9.jpg)
9
Group sequential design
An adaptive design that allows for prematurely stopping a trial due to safety, efficacy/futility, or bothbased on interim analysis results
Well-understood design without additional adaptations
Overall type I error rate may not be preserved when there are additional adaptations (e.g., changes in hypotheses and/or
study endpoints) there is a shift in target patient population
![Page 10: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/10.jpg)
10
Jennison & Turnbull’s book
![Page 11: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/11.jpg)
11
CAPTURE trial background
Treatment of unstable angina requiring balloon angioplasty Endpoint: composite of death, myocardial infarction, urgent
repeat angioplasty/bypass surgery within 30 days of treatment
Treatments: equal randomization to 2-arms Control: standard therapy (heparin and aspirin) Experimental: control + abciximab
Expected event rates: Control: pC = .15 Experimental: pE = .10
fixed design sample size – 1372 (80% power)
Lancet, 349: 1429–1435, 1997
![Page 12: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/12.jpg)
12
CAPTURE design with O’Brien−Fleming bounds
![Page 13: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/13.jpg)
13
CAPTURE design with asymmetric bounds
![Page 14: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/14.jpg)
14
Covariate-adjusted adaptive randomization in a sarcoma trial
Patients with advanced/metastatic unresectable soft tissue sarcoma
Initial proposal: a single-arm trial of gemcitabine + docetaxel (G+D) with the aim to compare the results to historical data on G
Proposal of a randomized trial of G+D versus G created ethical concerns
Solution – Bayesian Adaptive Randomization
Thall PF, Wathen JK, Stat Med. 2005 Jul 15; 24(13):1947-64.
![Page 15: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/15.jpg)
15
Treatment plan
Up to four 6-week stages of chemotherapy Evaluation at each stage: Response, Stable, Failure Treatment continues if S, terminates otherwise Important baseline covariates Leiomyosarcoma - yes or no (LMS) Previous prior pelvic radiation (PPR) ⇒ Four subgroups: (LMS, PPR), (Not LMS, PPR), (LMS,
No PPR), (Not LMS, No PPR)
![Page 16: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/16.jpg)
16
Randomization procedure
Use a Bayesian generalized logistic regression model for the probabilities of overall treatment success
The model is based on data accumulated so far in the study Model covariates include: treatment, stage, baseline
covariates (LMS & PPR), and treatment-covariate interactions
Calculate for the new patient the probability of successful G+D treatment, π
Randomize the subject to G+D with probability π
![Page 17: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/17.jpg)
17
Sample size re-estimation
An adaptive design that allows for sample size adjustment or re-estimation based on the observed data at interim analysis blinded or unblinded?
Sample size adjustment or re-estimation is usually performed based on the various criteria such as: variability conditional power reproducibility probability
Can we always start with a small number and perform sample size re-estimation at interim?
![Page 18: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/18.jpg)
18
The Allegro trial
Phase III study to evaluate the effect of laquinimod in RRMS patients
Planned sample size – 1000 patients (1:1) Recruitment period: 18 months Treatment duration – 24 months Very important secondary endpoint: Time to confirmed
disability progression Under study assumptions – 260 events needed to provide
85% power for the disability endpoint, to detect Hazard Ratio of 0.7
N Engl J Med 2012;366:1000-9.
![Page 19: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/19.jpg)
19
Just before end of recruitment
15 months after trial start, 80 events have been observed Are we going to reach 260 events?
Management veto increase in sample size Acceptable alternative – increase treatment duration to 30
months
![Page 20: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/20.jpg)
20
Strategy – Whitehead’s framework
Estimate the overall survivor function from the blinded data Construct illustrative survival functions for treatment
groups consistent with assumed treatment effect and observed overall survival
Check whether trial is likely to produce number of events needed
Drug Information Journal, Vol. 35, 1387–1400, 2001
![Page 21: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/21.jpg)
21
Implementation
Maximum likelihood estimation from blinded data
Estimated number of events: At 24 months – 134 (55% power) At 30 months – 165 (64% power) Decision – end the study as planned, at the end of 24
months of treatment
[ ]∏=
⋅−⋅⋅− +⋅⋅⋅==N
i
ttddCiiCE
iCiCii eeNidtL1
5.0),,1,),(;),(( λψλψλλλ
![Page 22: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/22.jpg)
22
What really happened
Actual number of events at end of study – 132, but… Sample size was eventually 1106 the effect was higher than assumed: HR=0.64
![Page 23: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/23.jpg)
23
Drop-the-losers design
A multiple stage adaptive design that allows dropping the inferior treatment groups
General principles drop the inferior arms retain the control arm may modify or add additional arms
It is useful where there are uncertainties regarding the dose levels
Problem: dropped may contain valuable information regarding dose response
![Page 24: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/24.jpg)
24
Adaptive treatment-switching
Allowing the investigator to switch a patient’s treatment from an initial assignment to an alternative treatment if there is evidence of lack of efficacy or safety of the initial treatment
Commonly employed in cancer trials In practice, a high percentage of patients may
switch due to disease progression Estimation of survival is a challenge A high percentage of switching subjects maylead
to a change in hypotheses to be tested. Sample size adjustment for achieving a desired
power is critical to the success of the study.
![Page 25: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/25.jpg)
25
Adaptive-hypotheses design
A design that allows change in hypotheses based on interim analysis results
Examples switch from a superiority hypothesis to a non-
inferiority hypothesis Can the non-inferiority margin be adapted? Sample size calculation/re-estimation is needed
change in study endpoints Switch primary and secondary endpoints Switch from the primary endpoint to a co-primary
endpoint or a composite endpoint
![Page 26: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/26.jpg)
26
Seamless design
Combining two separate trials into one trial and would use data from patients enrolled before and after the adaptation in the final analysis Learning phase (e.g., phase II) Confirmatory phase (e.g., phase III)
Addresses study objectives of individual studies Utilizes data collected from both phases for final analysis Is it efficient?
![Page 27: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/27.jpg)
27
Seamless design scheme
![Page 28: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/28.jpg)
28
Example (Jennison &Turnbull, 2006)
![Page 29: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/29.jpg)
29
The results
![Page 30: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/30.jpg)
30
Combining results - BK method
![Page 31: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/31.jpg)
31
Combining results - TSE method
![Page 32: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/32.jpg)
32
Multiple adaptive design
Any combinations of two or more adaptation Very flexible Very attractive Very complicated Statistical inference is often difficult, if not
impossible to obtain Very painful
![Page 33: Joseph Levy MedicReS World Congress 2013 - 1](https://reader034.fdocuments.in/reader034/viewer/2022042821/55d51930bb61eba1228b457c/html5/thumbnails/33.jpg)
33
Take home message
Adaptive Plan
… not Adaptive Plane